You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
前沿生物(688221.SH)2020年度預虧2.2億-2.4億元
格隆匯 01-20 18:03

格隆匯 1 月 20日丨前沿生物(688221.SH)公佈,經財務部門初步測算,預計2020年度實現營業收入約4300萬元到5100萬元,同比增長106.14%144.49%

預計2020年度歸屬於上市公司股東的淨利潤約虧損2.2億元到虧損2.4,增加虧損約2755.02萬元到4755.02萬元歸屬於上市公司股東扣除非經常性損益後的淨利潤虧損2.29億元到虧損2.49億元,增加虧損約2666.14萬元到4666.14萬元

公司核心產品艾博韋泰(商品名:艾可寧®)的目標醫院為傳染病專科定點醫院,為此次新型冠狀病毒肺炎的定點接治醫療機構,新冠疫情期間,艾滋病患者的接治受到了一定程度的影響,亦對公司2020年上半年產品銷售產生了較大的影響2020年下半年,隨着新冠疫情得到有效防控,傳染病專科定點醫院對艾滋病患者的接治得以恢復

公司加強市場推廣力度,積極開展學術會議及患者教育等活動加大團隊建設的投入,擴充一線市場推廣人員數量,快速提升產品在目標醫院的覆蓋率,報吿期內新增覆蓋的醫院數量同比增加137%。基於艾博韋泰(商品名:艾可寧®)作為注射、長效與口服藥不同的特點,以及其在臨牀應用中的安全性、有效性得到更進一步驗證,公司深耕已覆蓋定點醫療機構,提升產品在目標患者人羣的產品滲透率

報吿期,研發費用約1.3億1.4億元,同比增長4457.88萬元5457.88萬元增長52.19%63.89%主要為報吿期內對在研產品及儲備研發項目的投入有所增加

綜上所述,公司2020年度預計出現淨利潤為負的情況。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account